Back

Catecholaminergic polymorphic ventricular tachycardia: risk modulators in patients treated with beta-blockers

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Primary arrhythmia syndromes - Device treatment Antiarrhythmic Drug Treatment ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Deni Kukavica

ICS Maugeri - IRCCS Pavia, Pavia (Italy)

3 More presentations in this session

Presentation thumbnail
T-wave alternans poorly prognostic in primary prophylactic ICD patients: A prospective EU-CERT-ICD study
Doctor A. Pelli (Oulu, FI)
Abstract Slides Video
Presentation thumbnail
Three dimensional modelling of mutant Kir2.1 channel PIP2 interactions help stratify arrhythmia severity in Andersen Tawil syndrome type 1
Mrs L. Gutierrez (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Characteristics and prognosis of the catecholamine induced QT prolongation syndrome
Professor V. Probst (Nantes, FR)
Abstract Slides Video

Access the full session

Session thumbnail
Primary arrhythmia syndromes - Device treatment

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
First documented clinical case of arrhythmogenic heterozygous TECRL variant
thumbnail
Congress Presentation
Acute in vivo antiarrhythmic effects of cGMP-modifying drugs in the R2474S mouse model of catecholiminergic polymorphic ventricular tachycardia.
thumbnail
Congress Presentation
Racing hearts, calm minds: a guideline-driven approach to tackling non-sustained ventricular tachycardia

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources